Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 434-442

  Friel, Anne M ^a   Zhang, Ling ^a   Pru, Cindy A ^b   Clark, Nicole C ^b   McCallum, Melissa L ^b   Blok, Leen J ^c   Shioda, Toshi ^a   Peluso, John J ^d   Rueda, Bo R ^a   Pru, James K ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cancer; Chemotherapy; Endometrial; PGRMC1; Progesterone; Xenograft

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; MESSENGER RNA; PGRMC1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SIZE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE DELETION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG RESISTANCE; DRUG SCREENING; ENDOMETRIAL NEOPLASMS; ENZYME IMMUNOASSAY; GENETICS; HUMAN; METABOLISM; MITOSIS; NONOBESE DIABETIC MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; MITOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919460145     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.036     Document Type: Article

References (58)

1. American Cancer Society What are the key statistics about endometrial cancer? http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-key-statistics.
2. Hale G.E., Hughes C.L., Cline J.M. Endometrial cancer: hormonal factors, the perimenopausal "window of risk," and isoflavones. J. Clin. Endocrinol. Metab 2002, 87:3-15.
3. Gadducci A., Cosio S., Genazzani A.R. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit. Rev. Oncol. Hematol 2006, 58:242-256.
4. Simpson A.N., Feigenberg T., Clarke B.A., Gien L.T., Ismiil N., Laframboise S., et al. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecol. Oncol 2014, 133:229-233.
5. Kim Y.B., Holschneider C.H., Ghosh K., Nieberg R.K., Montz F.J. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997, 79:320-327.
6. Rose P.G. Endometrial carcinoma. N. Engl. J. Med 1996, 335:640-649.
7. Lentz S.S. Advanced and recurrent endometrial carcinoma: hormonal therapy. Semin. Oncol 1994, 21:100-106.
8. Cahill M.A. Progesterone receptor membrane component 1: an integrative review. J. Steroid Biochem. Mol. Biol 2007, 105:16-36.
9. Peluso J.J., Pru J.K. Non-canonical progesterone signaling in granulosa cell function. Reproduction 2014, 147:R169-R178.
10. Pru J.K., Clark N.C. PGRMC1 and PGRMC2 in uterine physiology and disease. Front. Neurosci 2013, 7:168.
11. Peluso J.J. Progesterone receptor membrane component 1 and its role in ovarian follicle growth. Front. Neurosci 2013, 7:99.
12. Meyer C., Schmid R., Scriba P.C., Wehling M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur. J. Biochem 1996, 239:726-731.
13. Nolte I., Jeckel D., Wieland F.T., Sohn K. Localization and topology of ratp28, a member of a novel family of putative steroid-binding proteins. Biochim. Biophys. Acta 2000, 1543:123-130.
14. Zhang L., Kanda Y., Roberts D.J., Ecker J.L., Losel R., Wehling M., et al. Expression of progesterone receptor membrane component 1 and its partner serpine 1 mRNA binding protein in uterine and placental tissues of the mouse and human. Mol. Cell. Endocrinol 2008, 287:81-89.
15. Peluso J.J., Pappalardo A., Losel R., Wehling M. Progesterone membrane receptor component 1 expression in the immature rat ovary and its role in mediating progesterone's antiapoptotic action. Endocrinology 2006, 147:3133-3140.
16. Peluso J.J., DeCerbo J., Lodde V. Evidence for a genomic mechanism of action for progesterone receptor membrane component-1. Steroids 2012, 77:1007-1012.
17. Ace C.I., Okulicz W.C. Microarray profiling of progesterone-regulated endometrial genes during the rhesus monkey secretory phase. Reprod. Biol. Endocrinol 2004, 2:54.
18. Chen J.I., Hannan N.J., Mak Y., Nicholls P.K., Zhang J., Rainczuk A., et al. Proteomic characterization of midproliferative and midsecretory human endometrium. J. Proteome Res 2009, 8:2032-2044.
19. Luciano A.M., Corbani D., Lodde V., Tessaro I., Franciosi F., Peluso J.J., et al. Expression of progesterone receptor membrane component-1 in bovine reproductive system during estrous cycle. Eur. J. Histochem 2011, 55:e27.
20. Keator C.S., Mah K., Slayden O.D. Alterations in progesterone receptor membrane component 2 (PGRMC2) in the endometrium of macaques afflicted with advanced endometriosis. Mol. Hum. Reprod 2012, 18:308-319.
21. Peluso J.J. Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer. Steroids 2011, 76:903-909.
22. Peluso J.J., Gawkowska A., Liu X., Shioda T., Pru J.K. Progesterone receptor membrane component-1 regulates the development and cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology 2009, 150:4846-4854.
23. Neubauer H., Clare S.E., Wozny W., Schwall G.P., Poznanovic S., Stegmann W., et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008, 10:R85.
24. Causey M.W., Huston L.J., Harold D.M., Charaba C.J., Ippolito D.L., Hoffer Z.S., et al. Transcriptional analysis of novel hormone receptors PGRMC1 and PGRMC2 as potential biomarkers of breast adenocarcinoma staging. J. Surg. Res 2011, 171:615-622.
25. Ruan X., Neubauer H., Yang Y., Schneck H., Schultz S., Fehm T., et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric 2012, 15:467-472.
26. Neubauer H., Ma Q., Zhou J., Yu Q., Ruan X., Seeger H., et al. Possible role of PGRMC1 in breast cancer development. Climacteric 2013, 16:509-513.
27. Hanekamp E.E., Kuhne L.M., Grootegoed J.A., Burger C.W., Blok L.J. Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice. Endocr. Relat. Cancer 2004, 11:831-841.
28. Moffat J., Grueneberg D.A., Yang X., Kim S.Y., Kloepfer A.M., Hinkle G., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124:1283-1298.
29. Smith S.L., Shioda T. Advantages of COS-1 monkey kidney epithelial cells as packaging host for small-volume production of high-quality recombinant lentiviruses. J. Virol. Methods 2009, 157:47-54.
30. Pru J.K., Lynch M.P., Davis J.S., Rueda B.R. Signaling mechanisms in tumor necrosis factor alpha-induced death of microvascular endothelial cells of the corpus luteum. Reprod. Biol. Endocrinol 2003, 1:17.
31. Kashiwagi A., DiGirolamo C.M., Kanda Y., Niikura Y., Esmon C.T., Hansen T.R., et al. The postimplantation embryo differentially regulates endometrial gene expression and decidualization. Endocrinology 2007, 148:4173-4184.
32. Jensen M.M., Jorgensen J.T., Binderup T., Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med. Imaging 2008, 8:16.
33. Hanekamp E.E., Gielen S.C., van Oosterhoud S.A., Burger C.W., Grootegoed J.A., Huikeshoven F.J., et al. Progesterone receptors in endometrial cancer invasion and metastasis: development of a mouse model. Steroids 2003, 68:795-800.
34. Peluso J.J., Romak J., Liu X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008, 149:534-543.
35. Peluso J.J., Liu X., Saunders M.M., Claffey K.P., Phoenix K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J. Clin. Endocrinol. Metab 2008, 93:1592-1599.
36. Engmann L., Losel R., Wehling M., Peluso J.J. Progesterone regulation of human granulosa/luteal cell viability by an RU486-independent mechanism. J. Clin. Endocrinol. Metab 2006, 91:4962-4968.
37. Runko E., Kaprielian Z. Caenorhabditis elegans VEM-1, a novel membrane protein, regulates the guidance of ventral nerve cord-associated axons. J. Neurosci 2004, 24:9015-9026.
38. Hughes A.L., Powell D.W., Bard M., Eckstein J., Barbuch R., Link A.J., et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab 2007, 5:143-149.
39. Losel R.M., Besong D., Peluso J.J., Wehling M. Progesterone receptor membrane component 1 - many tasks for a versatile protein. Steroids 2008, 73:929-934.
40. Suchanek M., Radzikowska A., Thiele C. Photo-leucine and photo-methionine allow identification of protein-protein interactions in living cells. Nat. Methods 2005, 2:261-267.
41. Selmin O., Lucier G.W., Clark G.C., Tritscher A.M., Vanden Heuvel J.P., Gastel J.A., et al. Isolation and characterization of a novel gene induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Carcinogenesis 1996, 17:2609-2615.
42. Hand R.A., Jia N., Bard M., Craven R.J. Saccharomyces cerevisiae Dap1p, a novel DNA damage response protein related to the mammalian membrane-associated progesterone receptor. Eukaryot. Cell 2003, 2:306-317.
43. Rohe H.J., Ahmed I.S., Twist K.E., Craven R.J. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol. Ther 2009, 121:14-19.
44. Liu L., Wang J., Zhao L., Nilsen J., McClure K., Wong K., et al. Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. Endocrinology 2009, 150:3186-3196.
45. Maeda Y., Ohtsuka H., Tomioka M., Oikawa M. Effect of progesterone on Th1/Th2/Th17 and regulatory T cell-related genes in peripheral blood mononuclear cells during pregnancy in cows. Vet. Res. Commun 2013, 37:43-49.
46. Lodde V., Peluso J.J. A novel role for progesterone and progesterone receptor membrane component 1 in regulating spindle microtubule stability during rat and human ovarian cell mitosis. Biol. Reprod 2011, 84:715-722.
47. Mir S.U., Ahmed I.S., Arnold S., Craven R.J. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int. J. Cancer 2012, 131:E1-E9.
48. Ahmed I.S., Rohe H.J., Twist K.E., Mattingly M.N., Craven R.J. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule. J. Pharmacol. Exp. Ther 2010, 333:564-573.
49. Xu J., Zeng C., Chu W., Pan F., Rothfuss J.M., Zhang F., et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat. Commun 2011, 2:380.
50. Crudden G., Loesel R., Craven R.J. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol 2005, 26:142-146.
51. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289:3243-3253.
52. Peluso J.J., Lodde V., Liu X. Progesterone regulation of progesterone receptor membrane component 1 (PGRMC1) sumoylation and transcriptional activity in spontaneously immortalized granulosa cells. Endocrinology 2012, 153:3929-3939.
53. Thomas P., Pang Y., Dong J. Enhancement of cell surface expression and receptor functions of membrane progestin receptor alpha (mPRalpha) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors. Endocrinology 2014, 155:1107-1119.
54. Peluso J.J., Yuan A., Liu X., Lodde V. Plasminogen activator inhibitor 1 RNA-binding protein interacts with progesterone receptor membrane component 1 to regulate progesterone's ability to maintain the viability of spontaneously immortalized granulosa cells and rat granulosa cells. Biol. Reprod 2013, 88:20.
55. Luciano A.M., Franciosi F., Lodde V., Tessaro I., Corbani D., Modina S.C., et al. Oocytes isolated from dairy cows with reduced ovarian reserve have a high frequency of aneuploidy and alterations in the localization of progesterone receptor membrane component 1 and aurora kinase B. Biol. Reprod 2013, 88:58.
56. Wendler A., Keller D., Albrecht C., Peluso J.J., Wehling M. Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. Oncol. Rep 2011, 25:273-279.
57. Liu N., Zhou C., Zhao J., Chen Y. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Invest 2012, 30:577-582.
58. Panda H., Chuang T.D., Luo X., Chegini N. Endometrial miR-181a and miR-98 expression is altered during transition from normal into cancerous state and target PGR, PGRMC1, CYP19A1, DDX3X, and TIMP3. J. Clin. Endocrinol. Metab 2012, 97:E1316-E1326.